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Abstract: Tamoxifen is widely used in breast cancer treatment and minimum steady-state concen-
trations of its active metabolite endoxifen (CSS,min ENDX) above 5.97 ng/mL have been associated
with favourable disease outcome. Yet, about 20% of patients do not reach target CSS,min ENDX ap-
plying conventional tamoxifen dosing. Moreover, 4–75% of patients are non-adherent, resulting in
worse disease outcomes. Assuming complete adherence, we previously showed model-informed
precision dosing (MIPD) to be superior to conventional and CYP2D6-guided dosing in minimising
the proportion of patients with subtarget CSS,min ENDX. Given the high non-adherence rate in long-
term tamoxifen therapy, this study investigated the impact of non-adherence on CSS,min ENDX target
attainment in different dosing strategies. We show that MIPD allows to account for the expected
level of non-adherence (here: up to 2 missed doses/week): increasing the MIPD target threshold
from 5.97 ng/mL to 9 ng/mL (the lowest reported CSS,min ENDX in CYP2D6 normal metabolisers)
as a safeguard resulted in the lowest interindividual variability and proportion of patients with
subtarget CSS,min ENDX even in non-adherent patients. This is a significant improvement to conven-
tional and CYP2D6-guided dosing. Adding a fixed increment to the originally selected dose is not
recommended, since it inflates interindividual variability.
Keywords: tamoxifen; non-adherence; model-informed precision dosing; pharmacokinetics;
pharmacometrics
1. Introduction
Tamoxifen is a selective modulator of the oestrogen receptor (ER), used for the treat-
ment of ER-positive breast cancer in pre- and postmenopausal patients [1,2]. While it
is also given in the neoadjuvant, palliative, and preventive setting, it is most often used
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for 5–10 years in the adjuvant setting [1,2]. The metabolism of tamoxifen is complex,
involving several polymorphic enzymes such as CYP2D6, CYP3A5, CYP2C9, CYP2C19 as
well as sulfotransferases and UDP-glucuronosyltransferases, respectively [3,4]. CYP2D6
plays a major role in the formation of endoxifen, tamoxifen’s most relevant and around
100-fold more active metabolite, resulting in a high interindividual variability in endoxifen
minimum concentrations at steady-state (CSS,min ENDX) [5–7]. Tamoxifen is taken orally at
20 mg once daily (QD) and although convenient, the patient may behave non-adherently.
Non-adherence, defined as <80% drug intake [8], is significantly associated with treatment
failure [9–11]. A therapeutic target for CSS,min ENDX of 5.97 ng/mL has been associated
with superior survival [6,7]. However, at the conventional dose of 20 mg, patients with
impaired or loss of CYP2D6 activity are at high risk of being below the target concentra-
tion, associated with a 26% higher breast cancer recurrence rate [7]. Reported adherence
rates in adjuvant or preventive tamoxifen treatment vary from 25% to 96% [8,10–16] and
associations made with non-adherence include young (<40–60 years) [12,15,17] and old age
(>75–85 years) [10,12,15,18], married status [19], current or previous smoking [10,20,21],
node-negative status [10], prior mastectomy [12], prior lumpectomy [15], comorbidities [15],
prior history of thromboembolic events [10], sequential treatment assignment with aro-
matase inhibitors [10,14], adverse events [16,18,22–24] and a low socio-economic back-
ground [19,20].
In our previous work, we compared three different tamoxifen early dose finding regi-
mens with an increasing degree of dose individualisation, assuming complete adherence
(100% drug intake) [25]: Conventional dosing, CYP2D6 genotype-predicted phenotype-
guided dosing (short: CYP2D6-guided dosing) and model-informed precision dosing
(MIPD) [26–28]. Amongst the three strategies, MIPD performed best both in terms of
target attainment (92.8%, compared to 84.0% and 77.8% in CYP2D6-guided and conven-
tional dosing, respectively) and lowest CSS,min ENDX interindividual variability (IIV). Given
the considerable concern of non-adherence to tamoxifen treatment, this study aimed to
explore the impact of later non-adherence on CSS,min ENDX target attainment in the three
described and two additional modified MIPD early dose finding strategies using stochas-
tic simulations. The simulation results showed that the risk for target non-attainment
due to later non-adherence increased with increasing level of dose individualisation dur-
ing the early dose finding stage. However, targeting the mean CSS,min ENDX in CYP2D6
genotype-predicted normal metabolisers (gNM) instead of the proposed therapeutic endox-
ifen threshold concentration, continued regular therapeutic drug monitoring, and including
risk factors for non-adherence in existing pharmacokinetic/pharmacodynamic models
used in MIPD can help preserve the value of MIPD in tamoxifen therapy, despite a high
prevalence for non-adherence.
2. Results
Given the definition of non-adherence (<80% drug intake [8], translating into 1.4
missed tamoxifen doses per week), we simulated a large cohort of 10,000 virtual patients
(in detail explained in the Methods section) amongst whom 60% were strictly adherent and
40% missed one or two consecutive tamoxifen doses per week over a period of six months
following an initial six month period of complete adherence (Figure 1). The percentages
of patients not reaching the proposed CSS,min ENDX therapeutic threshold concentration of
5.97 ng/mL [7] in adherent and non-adherent patients were analysed for
(i) Conventional dosing (20 mg QD);
(ii) CYP2D6-guided dosing (gNM: 20 mg, gIM: 30 mg, gPM: 60 mg QD);
(iii) MIPD targeting the proposed 5.97 ng/mL (initial CYP2D6-guided dosing for 4 weeks,
collection of virtual TDM samples at 2,3 and 4 weeks after treatment start and selection
of maintenance dose after week 4 using Bayesian Forecasting);
(iv) MIPD targeting 5.97 ng/mL (dosing strategy (iii)) when adding 10 mg to each selected
dose; and
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(v) MIPD (dosing strategy (iii)) but targeting the lowest reported mean CSS,min ENDX in
gNM (9 ng/mL) [29].
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In strictly adherent patients, the risks for subtarget CSS,min ENDX were lowest in MIPD
targeting CSS,min ENDX of 9 ng/mL, and in MIPD targeting 5.97 ng/mL when adding 10 mg
to each selected dose. The risk was moderately higher in MIPD targeting 5.97 ng/mL,
followed by CYP2D6 genotype-predicted phenotype-guided dosing and conventional
dosing (Figure 2 green box-whisker plots, Table 1). The IIV was lowest in MIPD target-
ing CSS,min ENDX of 5.97 ng/mL and 9 ng/mL, higher in MIPD targeting CSS,min ENDX of
5.97 ng/mL when adding 10 mg to each selected dose, and highest in CYP2D6-guided and
conventional dosing (Figure 2 and Supplementary Table S1).
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missed doses 1 2 1 2 1 2 1 2 1 2
Overall 26.4 33.3 14.8 21.1 22.3 42.8 0.525 3.02 0.375 1.55
gNM 13.2 19.0 13.2 19.0 22.1 42.1 0.00 0.530 0.132 1.15
gIM 36.8 45.8 14.8 21.3 20.5 40.4 0.594 2.91 0.198 1.32
gPM 90.1 92.8 32.4 41.4 36.9 65.3 5.41 29.3 4.05 7.21
Abbreviations: gNM, gIM, and gPM: genotype-predicted normal, intermediate, and poor metabolisers, respectively. Bold: dosing strategies
with lowest percentage of patients at risk having missed one or two doses, respectively.
Increases in risk for target non-attainment due to non-adherence increased with the
increasing level of dose individualisation and were inversely proportional to the (absolute)
risks for target non-attainment in strictly adherent patients. As expected, the risk of target
non-attainment increased with the number of missed doses as well as with the impairment
of CYP2D6 function (from gNM to gPM) (Table 1, Figure 3). Both modified MIPD dosing
strategies resulted in lower percentages of gNM and gIM at risk. However, compared to
MIPD targeting 9 ng/mL, MIPD targeting CSS,min ENDX of 5.97 ng/mL when adding 10 mg
to the selected dose resulted in a much higher IIV and a high percentage of non-adherent
gPMs at risk. Conversely, MIPD targeting 9 ng/mL resulted in low risks in non-adherent
patients across all genotype-predicted phenotypes. Furthermore, median CSS,min ENDX
were equivalent to the median CSS,min ENDX simulated in CYP2D6-guided dosing but with
significantly lower IIV (Supplementary Table S1). Thus, increasing the target level to
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9 ng/mL presents a safeguard to the uncertainty associated with the patient status and
physiology that is not captured and accounted for by covariates. Irrespective of the dose
individualisation strategy chosen, strict adherence to tamoxifen intake is most critical in
gPM patients.
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3. Discussion
Non-adherence is often observed in patients undergoing long-term tamoxifen treat-
ment and is a major concern due to its negative impact on disease outcome [9,10]. Further-
more, around 20% [7] of patients are considered at risk for CSS,min ENDX below a proposed
therapeutic threshold due to impaired CYP2D6 activity and additional high unexplained
IIV. Of note, tamoxifen adherence could significantly increase the explained variability
of endoxifen plasma concentrations in breast cancer patients [30]. An MIPD early dose
finding framework has been proposed to increase the proportion of patients reaching
target endoxifen concentrations and mitigate the high IIV observed in CSS,min ENDX [25].
However, later non-adherence in long-term therapy is usually not considered in MIPD
early dose finding frameworks. Continued regular TDM after initial dose titration could
help to identify non-adherent patients early on. However, this service is also expensive,
especially in long-term therapies, and is rarely feasible.
In this work, investigating the impact of non-adherence on different dosing strategies,
we identified adherence as a crucial factor for the success of MIPD early dose finding
strategies. While MIPD targeting the proposed therapeutic threshold concentration of
5.97 ng/mL is an excellent dosing strategy in strictly adherent patients, it performed worse
than CYP2D6-guided dosing in patients missing one dose per week and was worst in
patients missing two consecutive doses per week. In fact, almost half (42.8%) of MIPD
patients targeting the therapeutic target threshold were at risk for subtarget CSS,min ENDX
when two consecutive doses were missed after the initial dose finding stage. This finding
highlights an important feature of MIPD: precision dosing aims to identify the tailored dose
for an individual patient to reach a target exposure. A common assumption is that every
dose is taken correctly and, given that the dosing schedule is chosen to result in an exposure
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at but not significantly above the target and no uncertainty on adherence is taken into ac-
count, non-adherence will inevitably result in subtarget exposure. In our simulation study,
conventional dosing showed the least relative sensitivity to non-adherence as assessed by
the increase in risk relative to the baseline risk at complete adherence; however, the risks for
target non-attainment were the highest in strictly adherent patients and patients missing
one dose per week. Compared to conventional dosing, CYP2D6-guided dosing showed
lower proportions of patients at subtarget CSS,min ENDX in both non-adherence scenarios.
Two factors can explain this: first, CYP2D6-guided dosing allows for the majority of patients
to reach exposures above the target concentration. Second, because CYP2D6-guided dosing
does not consider the IIV in patients within CYP2D6 genotype-predicted phenotypes, large
IIV in CSS,min ENDX can be observed in CYP2D6-guided dosing (Figure 2, large range of
whiskers). This results in many individual concentrations being significantly above the
target concentration in adherent patients and lower, but not yet subtarget, concentrations in
non-adherent patients. Yet, as some individuals experience very high CSS,min ENDX, which
can lead to increased frequencies of adverse events [31–33], CYP2D6-guided dosing should
not be the dosing strategy of choice.
To further strengthen the advantages of MIPD by implementing a safeguard to non-
adherence, we explored two additional MIPD dosing strategies: dosing strategy (iv) adding
a fixed increment (here: 10 mg) to each individual selected dose in MIPD using the original
target, as it is commonly done in practice, or a dosing strategy (v) targeting a higher
CSS,min ENDX than the proposed therapeutic target threshold, i.e., the mean CSS,min ENDX in
gNM. There was a wide range (9.30–34.9 ng/mL) [29,34–38] of reported mean CSS,min ENDX
in gNM (formerly defined as genotype-predicted extensive metabolisers (gEM)) at con-
ventional dosing from which, as the most conservative approach, we chose the lowest
value (9 ng/mL [29]) for the increased PK target. In our simulations, both additional
dosing strategies resulted in reduced risks due to non-adherence (Figure 3) and over-
all CSS,min ENDX within the range of the CSS,min ENDX observed in conventional dosing
(Figure 2, Supplementary Table S1). Yet, due to the much higher IIV observed in dosing
strategy (iv) (additional 10 mg), introduced by the fixed dose increment, and the large risk
increase for gPM when missing two consecutive doses per week, this inferior approach can-
not be recommended. To prevent the large increase in IIV, a relative rather than an absolute
dose increase would be needed. Based on our simulation results, applying MIPD with a
higher target CSS,min ENDX of 9 ng/mL in patients with a high risk for non-adherence seems
favourable. MIPD targeting a CSS,min ENDX of 9 ng/mL results in median CSS,min ENDX
similar to the ones observed in CYP2D6-guided dosing (12.4 ng/mL vs. 12.9 ng/mL,
Supplementary Table S1). Moreover, due to the reduced IIV (24.1% CV vs. 56.8% CV,
Supplementary Table S1) it allows for almost all adherent patients to reach the proposed
therapeutic target concentration of 5.97 ng/mL (99.9% vs. 90.8%, Supplementary Table S1)
with minimal risk increases due to non-adherence (1.55% vs. 21.1% of patients at risk when
missing two consecutive doses per week, Table 2). Of note, the span of tamoxifen doses
in dosing strategy (v) is high, ranging from 5 mg QD to 120 mg QD. While we limited
our maximum dose to the highest dose tested without additional toxicities [36], the safety
of our proposed dosing framework has to be confirmed in a clinical trial before it can be
recommended for use in clinical routine.
Additional measures such as continued regular therapeutic drug monitoring after
initial therapeutic drug monitoring-based dose titration can aid in promptly identifying
non-adherent patients [11] and allows to keep using the original target CSS,min ENDX of
5.97 ng/mL. Finally, existing MIPD approaches for chronic/long-term treatments should
be extended (where appropriate) to account for the likelihood of non-adherence and
patient characteristics associated with it. Of note, the endoxifen PK target of 5.97 ng/mL
was proposed in a study, which did not account for non-adherence and allowed sample
collection up until four years after breast cancer diagnosis [7]. Thus, it cannot be excluded
that the cohort analysed in this study contained non-adherent patients. Yet, a similar
study in pre-menopausal patients [6], in which non-compliant patients (7% of all patients)
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were excluded for the clinical endpoint analysis, identified a PK target very similar to the
target proposed by Madlensky et al. [7] (5.29 ng/mL vs. 5.97 ng/mL) Thus, the possible
bias due to non-adherent patients in the Madlensky study would be small. Nevertheless,
a prospective well-designed trial with careful monitoring of adherence could aid in defining
a PK target with no potential bias due to non-adherence. Independent from this, as this
study focused on the impact of non-adherence on attaining a certain PK target instead of
the exact numerical value of the PK target itself, a change in the PK target would not result
in a change to our general findings.
Lastly, based on our pharmacokinetic model, our study was limited to the investiga-
tion of the impact of non-adherence on the tamoxifen/endoxifen exposure. Thus, given
steady-state attainment under non-adherence, the total duration of non-adherence would
not change the results of our study. However, as the total duration of non-adherence
certainly impacts the overall risk for breast cancer recurrence, future studies using a phar-
macodynamic model should focus on the impact of non-adherence and its duration on
clinical endpoints.
4. Materials and Methods
A previously published joint parent-metabolite nonlinear mixed-effects pharmacoki-
netic (PK) model of tamoxifen and endoxifen [39] with its final parameter estimates was
used for all simulations in this work. In short, the model consisted of a gut compartment
from which tamoxifen was characterised to be absorbed in a first-order process (ka) with
a lag time (tlag). Once absorbed, tamoxifen was characterised to distribute within a cen-
tral compartment (VTAM/F) and to be either eliminated by linear formation of endoxifen
(CL23/F) or by another linear elimination process (CL20/F) comprising other metabolic
pathways than to endoxifen. The metabolite endoxifen was characterised to distribute in a
central compartment (VENDX/F) and to be eliminated in a linear process (CL30/F). Three
covariate–PK parameter relationships were identified: the CYP2D6 genotype, implemented
as a fractional change model, had a significant impact on endoxifen formation (CL23/F),
while patient age and body weight, both implemented as power models, significantly
influenced the tamoxifen clearance to metabolites other than endoxifen (CL20/F). Interindi-
vidual variability components were implemented on the endoxifen formation and the
tamoxifen clearance to other metabolites. Model development and the criteria used for it
as well as an extensive covariate analysis, have been explained in detail in [25] and [39],
respectively. The simulations were performed in NONMEM 7.4., called through Perl speaks
NONMEM (PsN) v. 3.6.2 using the workbench Pirana v. 2.9.7 [40]. Pre- and postprocessing
was performed in R v. 3.5.1, accessed through RStudio Version 1.2.1184, using packages
Xpose4, ggplot2, plyr, dplyr and zoo.
To perform the simulation analyses, a large number of virtual breast cancer patients
(n = 10,000), representing the same frequency of covariates (CYP2D6 genotype, age, body
weight) as observed in the clinical PK database (n = 1388 patients) used for model develop-
ment, was generated. Concretely, representing the distribution of CYP2D6 activity scores
(AS) [41,42] in the model development dataset [39], the virtual population consisted of
56.6% CYP2D6 genotype-predicted normal metabolisers (gNM), defined as AS ≥1.5 and in-
cluding patients with missing AS imputed to AS 2, 37.8% genotype-predicted intermediate
metabolisers (gIM), defined as AS 0.5-1 and 5.6% genotype-predicted poor metabolisers
(gPM), defined as AS 0 [43]. Furthermore, for every virtual patient, a random age and
body weight value was sampled with replacement from the age and body weight values
recorded in the model development dataset.
The impact of one missed dose or two consecutive missed doses per week on endox-
ifen target (CSS,min ENDX > 5.97 ng/mL [7]) attainment was compared for different dosing
strategies with different levels of dose individualisation. Slightly modified from a previous
investigation [25], the first three dosing strategies were: (i) conventional dosing (20 mg
tamoxifen once daily (QD), (ii) CYP2D6-guided dosing (gNM: 20 mg QD, gIM: 30 mg
QD (adjusted from 40 mg QD upon classification of AS 1 as gIM instead of gNM [43]),
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PM: 60 mg QD) and (iii) model-informed precision dosing (MIPD). The rationales for
dosing strategies (i)–(iii) and detailed information on how MIPD was simulated were de-
scribed before [25]. In MIPD, the initial dose was based on the CYP2D6 genotype-predicted
phenotype and the maintenance dose was selected using Bayesian Forecasting based on
individual patient characteristics and three TDM samples taken at 2, 3 and 4 weeks after
treatment start. This MIPD design was the result of previous systematic investigations
regarding the optimal frequency and time points of TDM sampling [25]. Two additional
dosing strategies were explored regarding their potential to increase the forgiveness of
MIPD to non-adherence: (iv) MIPD targeting the proposed CSS,min ENDX therapeutic thresh-
old concentration of 5.97 ng/mL while adding a fixed increment (here: 10 mg) to each
individual dose, as it is common in current clinical practice [33,37,38,44] and (v) MIPD tar-
geting the lowest reported mean endoxifen CSS,min ENDX in gNM (9 ng/mL) [29]. As it is
common procedure to increase the dose in fixed increments, i.e., in 10 mg steps due to
available tablet strengths, the dosing strategy (iv) aimed to represent the status-quo of dose
adjustments to increase drug concentrations in clinical practice [33,37,38,44]. Representing
the common clinical practice to measure minimum concentrations [45], we chose to collect
our virtual TDM samples at the end of a dosing interval. However, as fluctuations in endox-
ifen concentrations within a steady-state dosing interval are minimal [46], our results are
also applicable to different times of sample collection once a steady-state has been attained.
To assess the impact of late non-adherence on endoxifen target attainment, 6 months
of full adherence (100% drug intake) were simulated for all dosing strategies (n = 10,000 pa-
tients each), assuring endoxifen steady-state attainment in all patients. Next, based on a
previous report [19] and to include a sufficient number of patients in both groups, 60% of
patients were simulated to stay fully adherent for the following 6 months. For the re-
maining 40%, two scenarios were simulated, in which patients missed either one dose
or two consecutive doses per week (corresponding to the non-adherence definition of
<80% correct medication intake [8] or 1.4 missed doses per week). Of note, in the second
6 months, patients continued to receive the dose determined at “treatment start”, i.e.,
in the first 6 months of complete adherence. No additional TDM samples were taken
during the second 6 months. After a total of 12 months, assuring new steady-state attain-
ment under non-adherence, the proportion of patients with CSS,min ENDX below the target
5.97 ng/mL (i.e., the number of patients at risk) in the adherent and non-adherent groups
in all dosing strategies were assessed overall and for different CYP2D6 genotype-predicted
phenotypes specifically.
Supplementary Materials: The following are available online at https://www.mdpi.com/1424-824
7/14/2/115/s1, Figure S1: Range and proportions of the individual dose selection in MIPD targeting
the proposed therapeutic target threshold of 5.97 ng/mL, Figure S2: Range and proportions of
the individual dose selection in MIPD targeting the lowest reported mean CSS,min ENDX in gNM
of 9 ng/mL, Figure S3: Range and proportions of the individual dose selection in MIPD targeting
the proposed therapeutic target threshold of 5.97 ng/mL and adding 10 mg to each selected dose,
Table S1: Comparison of CSS,min ENDX, interindividual variability and proportion in fully adherent
patients with subtarget concentrations in the five dosing strategies stratified in the three CYP2D6
genotype-predicted phenotypes with their individual doses.
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